Explore more publications!

Press Releases

Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting
Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026
The Greene School Students Begin Two-Year Journey: Assembly of RV-12 Aircraft Underway
New School Performance Information Available, North Dakota Schools Show Meaningful Gains in Choice Ready, Graduation Rates

New School Performance Information Available, North Dakota Schools Show Meaningful Gains in Choice Ready, Graduation Rates

New School Performance Information Available, North Dakota Schools Show Meaningful Gains in Choice Ready, Graduation Rates

New School Performance Information Available, North Dakota Schools Show Meaningful Gains in Choice Ready, Graduation Rates

Aerospace Materials Market Size, Share & Trends Analysis Report 2026- 2035
Gelteq Preclinical Study Demonstrates Enhanced Oral Delivery of Oil-Soluble and Poorly Soluble Drugs Using Its Gel-Based Platform
From Ancestry to Artistry: Mezzanine Gallery presents Renita Coursey’s “The Garden”

From Ancestry to Artistry: Mezzanine Gallery presents Renita Coursey’s “The Garden”

Accendatech US comments on the recent setback in phase 2 study to evaluate STAT3 as therapeutic target and other drug development strategies such as AI and precision medicine to treat patients with IPF
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025
Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ Platform
Dr. Garcia Announces Holiday Gift Discount and Flexible Payment Plans for Biomagnetism Online Training
Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA
Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies
Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Registration Open for School-Based Behavioral Health ECHO© Series

Registration Open for School-Based Behavioral Health ECHO© Series

Sustainability Day Summit: From Global Low-Carbon Systems to Student Impact
This Week in Construction: Top News, Blogs, Case Studies, Videos & Industry Trends – December 4, 2025
The Ritz-Carlton Leadership Center Announces Two Live Virtual Courses Designed to Elevate Service Outcomes in 2026

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions